Navigation Links
Bisexuality not a transitional phase among women, according to new research
Date:1/15/2008

WASHINGTON -- Bisexuality in women appears to be a distinctive sexual orientation and not an experimental or transitional stage that some women adopt "on their way" to lesbianism, according to new research published by the American Psychological Association.

The study of 79 non-heterosexual women over 10 years found that bisexual women maintained a stable pattern of attraction to both sexes. In addition, the research appears to have debunked the stereotype that bisexual women are uninterested in or unable to commit to long-term monogamous relationships.

"This research provides the first empirical examination of competing assumptions about the nature of bisexuality, both as a sexual identity label and as a pattern of nonexclusive sexual attraction and behavior," wrote University of Utah psychologist Lisa M. Diamond, PhD, who conducted the study. "The findings demonstrate considerable fluidity in bisexual, unlabeled and lesbian women's attractions, behaviors and identities and contribute to researchers' understanding of the complexity of sexual-minority development over the life span."

Results of the research were published in the January issue of Developmental Psychology, published by the APA. This special issue of the journal focuses on research into psychological topics concerning sexual orientation and gender identity.

Diamond used interview data collected five times over a decade from 79 women who identified as lesbian, bisexual or unlabeled. The subjects initially ranged in age from 18 to 25 years old.

Among Diamond's findings:

  • Bisexual and unlabeled women were more likely than lesbians to change their identity over the course of the study, but they tended to switch between bisexual and unlabeled rather than to settle on lesbian or heterosexual as their identities.

  • Seventeen percent of respondents switched from a bisexual or unlabeled identity to heterosexual during the study -- but more than half of these women switched back to bisexual or unlabeled by the end.

  • By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.

  • Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.

"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.


'/>"/>

Contact: Pam Willenz
pwillenz@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Seabrook House Opens Transitional Living Facility: Seabrook West
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. Cytopia Commences Phase II Cancer Drug Study
6. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
7. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
8. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
9. Early Phase II results show bosutinib safe, effective for CML
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
Breaking Medicine Technology: